Refine
Year of publication
Document Type
- Preprint (718)
- Article (703)
- Working Paper (6)
- Conference Proceeding (3)
- Doctoral Thesis (3)
- Report (2)
Has Fulltext
- yes (1435)
Is part of the Bibliography
- no (1435) (remove)
Keywords
- Heavy Ion Experiments (21)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- COVID-19 (4)
- Cancer (4)
- Collective Flow (4)
- Depression (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Biomarkers (3)
- Epilepsy (3)
- Genetics (3)
- Heavy Ions (3)
- Heavy Quark Production (3)
- Jets and Jet Substructure (3)
- Magnetic resonance imaging (3)
- Seizure (3)
- acute myeloid leukemia (3)
- pp collisions (3)
- Accelerators & Beams (2)
- Acute myeloid leukemia (2)
- Algorithms (2)
- Artificial intelligence (2)
- Atomic, Molecular & Optical (2)
- Beauty production (2)
- Biomarker (2)
- Bipolar disorder (2)
- Bone density (2)
- CT (2)
- CV9202 (2)
- Charm physics (2)
- Cohort studies (2)
- Collectivity (2)
- Correlation (2)
- Costs (2)
- Diffraction (2)
- Elastic scattering (2)
- Elliptic flow (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- FGFR (2)
- Frieden (2)
- Friedenskonferenz (2)
- Heavy-ion collisions (2)
- Immunology (2)
- Intensive care units (2)
- Lepton-Nucleon Scattering (experiments) (2)
- MRI (2)
- MSC (2)
- MSC2013 (2)
- Mitochondria (2)
- Multidetector computed tomography (2)
- München (2)
- Neoplasms (2)
- Non-small cell lung cancer (2)
- Oncology (2)
- Osteoporosis (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Pre-analytics (2)
- Psychiatric disorders (2)
- QCD (2)
- Quality of life (2)
- Quarkonium (2)
- Relativistic heavy-ion collisions (2)
- SARS-CoV-2 (2)
- Shear viscosity (2)
- Sicherheitskonferenz (2)
- Single electrons (2)
- Spine (2)
- Surgery (2)
- Tomography (2)
- Tomography (x-ray computed) (2)
- apoptosis (2)
- cabozantinib (2)
- childhood acute myeloid leukemia (2)
- computed tomography (2)
- growth inhibition (2)
- immunotherapy (2)
- land use (2)
- liver (2)
- lung cancer (2)
- penile cancer (2)
- portal hypertension (2)
- relapse (2)
- resistant cell lines (2)
- salvage therapy (2)
- security conference (2)
- squamous cell carcinoma (2)
- storage rings (2)
- targeted therapy (2)
- 19F (1)
- 3 mm RAS instruments (1)
- 3 mm instruments (1)
- 3years (1)
- 900 GeV (1)
- ABCB1 (1)
- ABCC1 (1)
- ABCG2 (1)
- ACLF (1)
- ADGRE1 (1)
- AKI (1)
- AKT (1)
- ALICE detector (1)
- ALK-rearranged NSCLC (1)
- APRI (1)
- Ablation Techniques (1)
- Accelerators & storage rings (1)
- Acquired drug resistance (1)
- Acquired resistance (1)
- Active middle ear implants (1)
- Acuris (1)
- Acute lymphoblastic leukemia (1)
- Acute lymphocytic leukaemia (1)
- Adolescents (1)
- Age determination by skeleton (1)
- Age groups (1)
- Aktienmarkt (1)
- Alpha-synuclein (1)
- Alternative oxidase (1)
- Alzheimer (1)
- Amino acid analysis (1)
- Amyloid precursor protein (1)
- Anemia (1)
- Angiography (1)
- Angiomyolipoma (1)
- Anti-nuclei (1)
- Anti-seizure medication (1)
- Anticonvulsant (1)
- Antifungal agents (1)
- Antiretroviral therapy (1)
- Antiretrovirals (1)
- Aortic valve replacement (1)
- Applikationen (1)
- Archaeogeophysics (1)
- Artificial Intelligence (1)
- Aspergillosis (1)
- Atomic & molecular beams (1)
- Auditory system (1)
- Autofreies Wohnen (1)
- Autologous stem cell transplantation (1)
- Automated Tube Potential Selection (1)
- Autoreduziertes Wohnen (1)
- Awareness campaign (1)
- B cell receptor (1)
- B-slope (1)
- BI1361849 (1)
- Beam loss (1)
- Behavior (1)
- Behavioral disorders (1)
- Bike-Sharing (1)
- Biodiversity (1)
- Biodiversity Data (1)
- Biogeochemistry (1)
- Biological heart valves (1)
- Biomonitoring (1)
- Bioprosthesis (1)
- Biopsy (1)
- Bleeding (1)
- Blood (1)
- Blood sample handling (1)
- Bloodstream infections (1)
- Bone conduction devices (1)
- Bone diseases, Metabolic (1)
- Bone marrow (1)
- Boosted Jets (1)
- Botanical Collections (1)
- Brachiopoda (1)
- Brachiozoa (1)
- Breathing (1)
- Bryozoa (1)
- Business strategy in drug development (1)
- C-reactive protein (1)
- CABG (1)
- CAD/ CAM crown (1)
- CAKUT (1)
- CNDAC (1)
- COMT (1)
- CRPC (1)
- CT dual-energy computed tomography (1)
- CT pulmonary angiography (1)
- CT radiation exposure (1)
- CT-guidance (1)
- CTLA-4 (1)
- Calcium (1)
- Cancer Staging (1)
- Cancer check up (1)
- Cancer staging (1)
- Car-Sharing (1)
- Carbon cycle (1)
- Cardiac surgery (1)
- Carsharing (1)
- Cell membranes (1)
- Central Europe (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Charge-transfer collisions (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Checkpoint inhibitor (1)
- Chemicals of emerging concern (1)
- Chemoembolization (1)
- Chemotherapy (1)
- Child abuse (1)
- Childhood abuse (1)
- Children (1)
- Chondral Lesion (1)
- Circular accelerators (1)
- Cirrhosis (1)
- Cleanliness level (1)
- Climate-change ecology (1)
- Clinical genetics (1)
- Clinical trial (1)
- Clinical variation (1)
- Coalescence (1)
- Cochlear implantation (1)
- Cold nuclear matter effects (1)
- Collective Flow, (1)
- Colon capsule endoscopy (1)
- Combined immune checkpoint blockade (1)
- Combo® DTS (1)
- Community ecology (1)
- Comparison with QCD (1)
- Complementation rate (1)
- Complex II (1)
- Complex posttraumatic stress disorder (1)
- Compositional bias (1)
- Computed tomography pulmonary angiography (CTPA) (1)
- Computed tomography, X-ray (1)
- Computer-aided drug design (1)
- Cone-beam computed tomography (1)
- Congenital anomalies (1)
- Consensus statement (1)
- Conservation (1)
- Conservation biology (1)
- Contrast agent (1)
- Couch tracking (1)
- Critical point (1)
- Cryoelectron microscopy (1)
- DCK (1)
- DME (1)
- DNA sequence analysis (1)
- DNA taxonomy (1)
- DNA-PAINT (1)
- DSM (1)
- Darmstadt (1)
- Data sharing (1)
- Deuteron production (1)
- Di-hadron correlations (1)
- Diagnostic imaging (1)
- Diagnostic markers (1)
- Dialectical behavioural therapy (1)
- Digitization (1)
- Direct oral anticoagulation (1)
- Direct reactions (1)
- Drug screens (1)
- Drug therapy (1)
- Dual-Source CT (1)
- Dual-energy computed tomography (1)
- EGFR (1)
- EMR1 (1)
- ETP-ALL (1)
- East–west divide (1)
- Eating disorders (1)
- Ecological modelling (1)
- Ecological networks (1)
- Ecosystem ecology (1)
- Ectoprocta (1)
- Edema (1)
- Elderly (1)
- Electric stimulation (1)
- Electron-pion identification (1)
- Electronic transitions (1)
- Electroweak interaction (1)
- Elektromobilität (1)
- Ellenberg indicator values (1)
- Embryos (1)
- Endocannabinoids (1)
- Environmental impact (1)
- European stock markets (1)
- Europäische Aktienmärkte (1)
- Europäische Union (1)
- Everolimus (1)
- Evidence-based guidelines (1)
- Exudates and transudates (1)
- Eye movements (1)
- F4/80 (1)
- FBS (1)
- FFLU (1)
- FIB-4 (1)
- FLT3 (1)
- Facial nerve (1)
- Fahrradverleihsysteme (1)
- Feasibility studies (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Flottenkonzepte (1)
- Forest ecology (1)
- Forschung (1)
- Frailty (1)
- Full waveform (1)
- Functional outcomes (1)
- GPS collar (1)
- GWAS (1)
- Gene expression (1)
- General practitioners (1)
- Gimbaled tracking (1)
- Glioblastoma survival (1)
- Global positioning system (1)
- Gram negative bacteria (1)
- Groomed jet radius (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- HBT (1)
- HBV (1)
- HCC (1)
- HIV (1)
- HIV-1 (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hadronization (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Head and neck cancer (1)
- Health information (1)
- Health policy (1)
- Health-seeking behaviour (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ion collisions (1)
- Heavy ions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Hedgehog pathway (1)
- Helpline (1)
- Hematologic malignancies (1)
- Hematology (1)
- Hematopoietic stem cell transplantation (1)
- Hepatitis C virus (1)
- Herbaria (1)
- Herniated disk (1)
- Hif-1 alpha (1)
- High-dose chemotherapy (1)
- Higher moments (1)
- Hodgkin lymphoma (1)
- Hsp70 (1)
- Hypertension (1)
- Hypochondriasis (1)
- Hypofractionated radiotherapy (1)
- ICL (1)
- ICL V4c (1)
- IHC (1)
- ILUVIEN (1)
- INR (1)
- Image processing (1)
- Image processing (computer-assisted) (1)
- Immunogenetics (1)
- Immunomonitoring (1)
- In-TIPS thrombosis (1)
- Inclusive spectra (1)
- Incomplete colonoscopy (1)
- Inflammation (1)
- Intensity interferometry (1)
- Interference fragmentation function (1)
- International normalized ratio (1)
- Interpretation (1)
- Intervertebral disc displacement (1)
- Intrinsic resistance (1)
- Invariant Mass Distribution (1)
- Invasive candidiasis (1)
- Inversion (1)
- Ionisation energy loss (1)
- Ipilimumab (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- K3EDTA plasma sampling (1)
- KDIGO (1)
- Kidney (1)
- Knockout (1)
- Kryptrochozoa (1)
- LVSPE (1)
- Ladeinfrastruktur (1)
- Lehre (1)
- Lenalidomide (1)
- Leukemia (1)
- Leukemias (1)
- Library screening (1)
- Lincoln-Siedlung (1)
- Lipidol (1)
- Lipidomics (1)
- Liver (1)
- Liver diseases (1)
- Liver transplantation (1)
- Local control (1)
- Lophophorata (1)
- Low & intermediate-energy accelerators (1)
- Low volume prep (1)
- Low-molecular-weight heparin (1)
- Luciferase (1)
- MALAT1 (1)
- MEDIC (1)
- MLC tracking (1)
- MTOR inhibitor (1)
- MYC (1)
- Mass spectrometry (1)
- Mastoiditis (1)
- Material budget (1)
- Medical Oncology (1)
- Melanoma (1)
- Mental health and psychiatry (1)
- Meriç River (1)
- Metabolomics (1)
- Metastasis (1)
- Micropollutants (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Mitfahrangebote (1)
- Mitochondrial disease (1)
- Mitoxantrone (1)
- Mixed hearing loss (1)
- Mixture risk assessment (1)
- Mobil-Stationen (1)
- Mobilität (1)
- Mobilitätskonzept (1)
- Mobilitätsstationen (1)
- Mobilitätsverhalten (1)
- Model of evolution (1)
- Molecular diagnostic testing (1)
- Monte Carlo (1)
- Moviprep (1)
- Multi-Parton Interactions (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multidetector Computed Tomography (1)
- Multifaktorenmodelle (1)
- Multimodalität (1)
- Multiple factor models (1)
- Multiple myeloma (1)
- Multiple parton interactions (1)
- Multivariate analysis (1)
- Mutation databases (1)
- Mycoses (1)
- Myocarditis (1)
- Myopia (1)
- NAFLD (1)
- NK cells (1)
- NMR spectroscopy (1)
- NOTCH (1)
- NOTCH1 (1)
- NSF (1)
- NVBP (1)
- Net-charge correlations (1)
- Net-charge fluctuations (1)
- Neural network (1)
- Neuronal morphology (1)
- Neuroscience (1)
- Neutropenia (1)
- Nivolumab (1)
- Nuclear modification factor (1)
- Nuclear reactions (1)
- Nuclear structure & decays (1)
- Nucleon induced nuclear reactions (1)
- ORL (1)
- Obsessive-compulsive disorder (1)
- Oldest-old (1)
- Organ motion (1)
- Osteoporotic fractures (1)
- Otorhinolaryngology (1)
- Oxidative phosphorylation (1)
- Oxygen (1)
- PD-1 (1)
- PD-L1 (1)
- PLX4032 (1)
- PLX4720 (1)
- PRoMPT (1)
- PSA screening (1)
- PSA-Screening (1)
- PTEN (1)
- PYTHIA (1)
- Parken (1)
- Parkinson’s disease (1)
- Particle and Resonance Production (1)
- Patellofemoral Joint (1)
- Patterns of care (1)
- Pb–Pb (1)
- Pedelecs (1)
- Personenmobilität (1)
- Phakic (1)
- Phantoms (imaging) (1)
- Phoronida (1)
- Phosphate (1)
- Phospho-soda (1)
- Phosphorylation (1)
- Photon counting (1)
- Phylloscopidae (1)
- Phylloscopus (1)
- Phylogeography (1)
- PillCamColon2 (1)
- Plasma (1)
- Point-of-care testing (1)
- Polarization (1)
- Polyps (1)
- Polysomnography (1)
- Polyzoa (1)
- Positive fluid balance (1)
- Positron emission tomography (1)
- Post-traumatic stress disorder (1)
- Postoperative atrial fibrillation (1)
- Preventive medicine (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Prostata-specific antigen (1)
- Prostataspezifisches Antigen (1)
- Proton-proton collisions (1)
- Proton–proton (1)
- Proton–proton collisions (1)
- Prävention (1)
- Psoriasis vulgaris (1)
- Psychological and psychosocial issues (1)
- Pulmonary embolism (1)
- QGP (1)
- QSARs (1)
- Quantitative Imaging (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- RHIC (1)
- RNA (1)
- RNA, long noncoding (1)
- RNActive (1)
- RSL curve (1)
- Radiation detectors (1)
- Radical prostatectomy (1)
- Radiology (1)
- Radiomics (1)
- Radiotherapy (1)
- Randomised controlled trial (1)
- Rapidity Range (1)
- Rare diseases (1)
- Region Rhein-Main (1)
- Registries (1)
- Rehabilitation (1)
- Relapse (1)
- Relativistic heavy ion physics (1)
- Renal cell carcinoma (1)
- Research (1)
- Research Infrastructure (1)
- Residency (1)
- Resolution Parameter (1)
- Respiration (1)
- Respiratory chain (1)
- Retro-IDEAL (1)
- Retrospective studies (1)
- Retrospective study (1)
- Rhabdomyoma (1)
- Ribosome (1)
- Risk drivers (1)
- River pollution (1)
- Robotic tracking (1)
- SAMHD1 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SCCHN (1)
- SLC20A1 (1)
- SMAD (1)
- SPSS (1)
- STIR (1)
- Salivary gland carcinoma (1)
- Sampling protocol (1)
- Sapacitabine (1)
- Second-line treatment (1)
- Seicercus (1)
- Semantics (1)
- Senescence (1)
- Sequence (1)
- Serum (1)
- Shell model (1)
- Single muons (1)
- Sleep (1)
- Sleep deprivation (1)
- Small molecules (1)
- Social anxiety disorder (1)
- Sociodemographic characteristics (1)
- SoftDrop (1)
- Specialist training (1)
- Spectroscopic factors & electromagnetic moments (1)
- Spinal fractures (1)
- Spine density (1)
- Splitting function (1)
- Stenotrophomonas maltophilia (1)
- Steroid (1)
- Subependymal giant cell astrocytoma (1)
- Surface waters (1)
- Surveys (1)
- Survival analysis (1)
- Survival data (1)
- Systematic Uncertainty (1)
- Systemic treatment (1)
- T-ALL (1)
- TGFβ (1)
- TGR(mREN2)27 (1)
- TIPS (1)
- TP53 mutation status (1)
- TR (1)
- TSC (1)
- Target screening (1)
- Targeted therapy (1)
- Taxonomy (1)
- Teaching (1)
- Technical data (1)
- Telemedicine (1)
- Territorial songs (1)
- Therapeutic anticoagulation (1)
- Thermal model (1)
- Time Projection Chamber (1)
- Tracking (1)
- Traditional Chinese Medicine (TCM) (1)
- Transcriptome analysis (1)
- Transition radiation detector (1)
- Transjugular Intrahepatic Portosystemic Shunt (1)
- Transverse momentum (1)
- Transversity (1)
- Treatment (1)
- Trigger (1)
- Tyrosine kinase inhibitor mTOR inhibition (1)
- USP28 (1)
- Umweltbilanz (1)
- University hospitals (1)
- Universitätskliniken (1)
- Urinary continence (1)
- Urinary incontinence (1)
- Ursus arctos (1)
- Uveal melanoma (1)
- VEGFR (1)
- Vaccination (1)
- Valve surgery (1)
- Vasculitis (1)
- Vector Boson Production (1)
- Vemurafenib (1)
- Vesicles (1)
- Vincristine (1)
- Virtual noncalcium reconstructions (1)
- Vorsorgeuntersuchung (1)
- Weiterbildung (1)
- Western diet (1)
- Wohnumzug (1)
- X-ray computed (1)
- X-rays (1)
- Xenon-based gas mixture (1)
- abdominal imaging (1)
- accessory proteins (1)
- acoustic radiation force impulse imaging (1)
- activity sensors (1)
- acute decompensation (1)
- acute lymphoblastic leukemia (1)
- acute-on-chronic liver failure (1)
- adjuvant chemotherapy (1)
- aegean (1)
- age (1)
- amino acids (1)
- amphiregulin (1)
- amygdalin (1)
- anaplastic large cell lymphoma (1)
- angiography (1)
- anterior chamber depth changes (1)
- anti-EGFR therapy (1)
- antiepileptic drugs (1)
- antimicrobial stewardship (1)
- antiviral therapy (1)
- aortic stenosis (1)
- archeological sea-level limiting points (1)
- artesunate (ART) (1)
- artifacts (1)
- artificial intelligence (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- autophagy (1)
- bacterial leakage (1)
- beads (1)
- bioactivity testing (1)
- biogeographic legaciese (1)
- bioindication (1)
- biomarker (1)
- bladder cancer (BCa) (1)
- bladder exstrophy-epispadias complex (1)
- breast cancer (1)
- brown bear (1)
- c-MET (1)
- cabazitaxel (1)
- carbapenem resistance (1)
- cardiac arrest (1)
- cardiac remodeling (1)
- case study (1)
- castration resistance (1)
- cataract surgery (1)
- cell lines (1)
- cell therapy (1)
- cell-free protein synthesis (1)
- characteristic species (1)
- chemorefractory metastatic colorectal cancer (1)
- children and adolescents (1)
- chronic total occlusion (1)
- cilia (1)
- cirrhosis (1)
- cisplatin resistance (1)
- cloacal malformation (1)
- coastal geomorphology (1)
- colorectal cancer (1)
- complementary/alternative medicine (CAM) (1)
- computer tomography (1)
- computer-assisted (1)
- conical coupling (1)
- conometric connection (1)
- corneas (1)
- cryptic species (1)
- cytarabine dose (1)
- dE/dx (1)
- data quality (1)
- depression (1)
- deswelling (1)
- detector (1)
- diagnostic imaging (1)
- differentiating species (1)
- disease prevalence (1)
- docetaxel (1)
- docetaxel (DX) resistance (1)
- drug resistance (1)
- dual-energy (1)
- easyPACId (1)
- ectosomes (1)
- effective lens position (1)
- elderly (1)
- electrical resistivity tomography (1)
- electroencephalography (EEG) (1)
- eltrombopag (1)
- energy-dispersive x-ray spectroscopy (1)
- epigenomics (1)
- epiregulin (1)
- ethical trade-off (1)
- eutrophication (1)
- excitation (1)
- exosomes (1)
- experimental results (1)
- explainable AI (1)
- extinction (1)
- extracellular vesicles (1)
- fear conditioning (1)
- fibrotest (1)
- fluorine (1)
- foraminifera (1)
- foraminifers (1)
- forest classification (1)
- forest functional similarity (1)
- fragment-based screening (1)
- functional genetics (1)
- gadobutrol (1)
- gene family (1)
- genetic generalized epilepsy (1)
- genome evolution (1)
- geophysical prospections (1)
- germ cell tumors (1)
- glioblastoma (1)
- glioblastoma survival (1)
- global change (1)
- graft rejection (1)
- graft-versus host (1)
- grasshopper communities (1)
- guidelines (1)
- habitat destruction (1)
- head-and-neck cancer (1)
- health information exchange (1)
- healthcare (1)
- heart failure (1)
- heavy ion experiments (1)
- hepatic encephalopathy (1)
- hepatocellular carcinoma (1)
- high-pitch (1)
- highly-charged ions (1)
- histology (1)
- hospital exemption (1)
- human cytomegalovirus (1)
- human knockout model (1)
- hypertension, pulmonary (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- immunity (1)
- immunohistochemistry (1)
- in vivo dosimetry (1)
- infection control (1)
- integrative taxonomy (1)
- interoperability (1)
- interventional radiology (1)
- intraarterial therapy (1)
- intrinsically disordered region (1)
- invasive species (1)
- iron chelation (1)
- ischemic type biliary lesions (1)
- keratoplasty (1)
- kidney formation (1)
- kinase inhibitor (1)
- knockout mouse (1)
- lamotrigine (1)
- learning (1)
- levetiracetam (1)
- liver fibrosis (1)
- liver metastases (1)
- liver metastasis (1)
- liver transplantation (1)
- livermetastases of colorectal cancer (1)
- local radiotherapy (1)
- locoregional chemotherapy (1)
- long non-coding RNA (1)
- low-dose imaging (1)
- mRNA active cancer immunotherapy (1)
- mRNA vaccine (1)
- mTOR (1)
- mTOR inhibitor (1)
- macrophage (1)
- magnetic gradiometry (1)
- marginal fit (1)
- marker (1)
- medial prefrontal cortex (mPFC) (1)
- memory consolidation and extinction (1)
- mesenchymal stromal cell (1)
- metastasis (1)
- metastatic prostate cancer (1)
- microdosing (1)
- microkeratome (1)
- microlaparoscopy (1)
- micropalaeontology (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- minimally invasive surgery (1)
- molecular characteristics (1)
- mortality (1)
- motility (1)
- multicenter study (1)
- multidetector computed tomography (1)
- multivariate mixed model (1)
- natural products (1)
- necroptosis (1)
- neovascularization, physiologic (1)
- neutralizing antibodies (1)
- nitrogen deposition (1)
- nocardia (1)
- nocardiosis (1)
- non-invasive fibrosis assessment (1)
- non-small cell lung cancer (1)
- nonstructural proteins (1)
- optical coherence tomography (1)
- orthology (1)
- orthopic liver transplantation (1)
- ovary (1)
- p+p collisions (1)
- pIOL (1)
- pediatric (1)
- pediatric patients (1)
- pediatric robotic surgery (1)
- personality (1)
- pharmacoresistance (1)
- phylogenetic community distance (1)
- phylogenetic signal (1)
- point shear wave elastography (1)
- portal vein (1)
- portosystemic shunt (1)
- predictive biomarkers (1)
- prognostic biomarker (1)
- prostate cancer (1)
- prostate cancer (PCa) (1)
- proteins (1)
- proteobacteria (1)
- proteomics (1)
- pseudoexfoliative syndrome (1)
- pulmonary embolism (1)
- pulmonary nocardiosis (1)
- qualitative research (1)
- quality control (1)
- quantum electrodynamics test (1)
- quark gluon plasma (1)
- radiation dosage (1)
- radiation dosimetry (1)
- radiation protection (1)
- radiomics (1)
- rare diseases (1)
- rats (1)
- re-exposure (1)
- rechallenge (1)
- recurrence pattern (1)
- refractory aGvHD (1)
- reintroduction (1)
- relativistic collisions (1)
- renal impairment (1)
- repeatability (1)
- reproducibility (1)
- resistance (1)
- retrospective trial (1)
- rigor (1)
- robotically assisted surgery (1)
- robotics (1)
- schizophrenia (1)
- sea-level indicator (1)
- semi-dry grassland (1)
- sequential ALK-inhibitor therapy (1)
- sex (1)
- shikonin (SHI) (1)
- simplified production (1)
- single subject classification (1)
- smart home (1)
- smart living (1)
- soil nutrients (1)
- song evolution (1)
- spectra (1)
- sphingolipids (1)
- spike protein (1)
- spontaneous portosystemic shunt (1)
- stage II/III colorectal cancer (1)
- standardization (1)
- steroid-resistant aGvHD (1)
- strong Coulomb field (1)
- structural habitat types (1)
- structural proteins (1)
- survival (1)
- temporal classification (1)
- testis (1)
- therapeutic anticoagulation (1)
- thrombopietin receptor agonist (1)
- thrombosis (1)
- tivantinib (1)
- transcranial magnetic stimulation (TMS) (1)
- transient elastography (1)
- transmission (1)
- transplantation (1)
- treatment resistance (1)
- tropical forests (1)
- trust (1)
- trustworthy AI (1)
- tumor microenvironment (1)
- tyrosine kinase inhibitor (TKI) (1)
- urinary tract development (1)
- uveal melanoma (1)
- valproic acid (1)
- variants of concern (1)
- vegetation-plot data (1)
- web of things (1)
- whole-genome sequencing (1)
- x-ray techniques (1)
- zebrafish development (1)
- Öffentlichkeit (1)
- ΔNp63 (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1124)
- Frankfurt Institute for Advanced Studies (FIAS) (995)
- Informatik (925)
- Medizin (166)
- Geowissenschaften (39)
- Institut für Ökologie, Evolution und Diversität (14)
- Biowissenschaften (13)
- Biodiversität und Klima Forschungszentrum (BiK-F) (10)
- Senckenbergische Naturforschende Gesellschaft (8)
- ELEMENTS (7)
The first study of ϕ-meson production in p–Pb collisions at forward and backward rapidity, at a nucleon–nucleon centre-of-mass energy √sNN=5.02 TeV, has been performed with the ALICE apparatus at the LHC. The ϕ-mesons have been identified in the dimuon decay channel in the transverse momentum (pT) range 1<pT<7 GeV/c, both in the p-going (2.03<y<3.53) and the Pb-going (−4.46<y<−2.96) directions — where y stands for the rapidity in the nucleon–nucleon centre-of-mass — the integrated luminosity amounting to 5.01±0.19 nb−1 and 5.81±0.20 nb−1, respectively, for the two data samples. Differential cross sections as a function of transverse momentum and rapidity are presented. The forward–backward ratio for ϕ-meson production is measured for 2.96<|y|<3.53, resulting in a ratio ∼0.5 with no significant pT dependence within the uncertainties. The pT dependence of the ϕ nuclear modification factor RpPb exhibits an enhancement up to a factor 1.6 at pT=3–4 GeV/c in the Pb-going direction. The pT dependence of the ϕ-meson cross section in pp collisions at √s=2.76 TeV, which is used to determine a reference for the p–Pb results, is also presented here for 1<pT<5 GeV/c and 2.5<y<4, for a 78±3 nb−1 integrated luminosity sample.
ϕ meson measurements provide insight into strangeness production, which is one of the key observables for the hot medium formed in high-energy heavy-ion collisions. ALICE measured ϕ production through its decay in muon pairs in Pb–Pb collisions at sNN−−−√=2.76 TeV in the intermediate transverse momentum range 2<pT<5 GeV/c and in the rapidity interval 2.5<y<4. The ϕ yield was measured as a function of the transverse momentum and collision centrality. The nuclear modification factor was obtained as a function of the average number of participating nucleons. Results were compared with the ones obtained via the kaon decay channel in the same pT range at midrapidity. The values of the nuclear modification factor in the two rapidity regions are in agreement within uncertainties.
Inclusive ϒ(1S) and ϒ(2S) production have been measured in Pb–Pb collisions at the centre-of-mass energy per nucleon–nucleon pair √sNN = 5.02 TeV, using the ALICE detector at the CERN LHC. The ϒ mesons are reconstructed in the centre-of-mass rapidity interval 2.5 < y < 4 and in the transversemomentum range pT < 15 GeV/c, via their decays to muon pairs. In this Letter, we present results on the inclusive ϒ(1S) nuclear modification factor RAA as a function of collision centrality, transverse momentum and rapidity. The ϒ(1S) and ϒ(2S) RAA, integrated over the centrality range 0–90%, are 0.37± 0.02(stat) ± 0.03(syst) and 0.10 ± 0.04(stat) ± 0.02(syst), respectively, leading to a ratio Rϒ(2S) AA /Rϒ(1S) AA of 0.28±0.12(stat)±0.06(syst). The observed ϒ(1S) suppression increases with the centrality of the collision and no significant variation is observed as a function of transverse momentum and rapidity.
Inclusive Υ(1S) and Υ(2S) production have been measured in Pb-Pb collisions at the centre-of-mass energy per nucleon-nucleon pair sNN−−−√=5.02 TeV, using the ALICE detector at the CERN LHC. The Υ mesons are reconstructed in the centre-of-mass rapidity interval 2.5<y<4 and in the transverse-momentum range pT<15 GeV/c, via their decays to muon pairs. In this Letter, we present results on the inclusive Υ(1S) nuclear modification factor RAA as a function of collision centrality, transverse momentum and rapidity. The Υ(1S) and Υ(2S) RAA, integrated over the centrality range 0-90%, are 0.37±0.02(stat)±0.03(syst) and 0.10±0.04(stat)±0.02(syst), respectively, leading to a ratio RΥ(2S)AA/RΥ(1S)AA of 0.28±0.12(stat)±0.06(syst). The observed Υ(1S) suppression increases with the centrality of the collision and no significant variation is observed as a function of transverse momentum and rapidity.
Inclusive Υ(1S) and Υ(2S) production have been measured in Pb-Pb collisions at the centre-of-mass energy per nucleon-nucleon pair sNN−−−√=5.02 TeV, using the ALICE detector at the CERN LHC. The Υ mesons are reconstructed in the centre-of-mass rapidity interval 2.5<y<4 and in the transverse-momentum range pT<15 GeV/c, via their decays to muon pairs. In this Letter, we present results on the inclusive Υ(1S) nuclear modification factor RAA as a function of collision centrality, transverse momentum and rapidity. The Υ(1S) and Υ(2S) RAA, integrated over the centrality range 0-90%, are 0.37±0.02(stat)±0.03(syst) and 0.10±0.04(stat)±0.02(syst), respectively, leading to a ratio RΥ(2S)AA/RΥ(1S)AA of 0.28±0.12(stat)±0.06(syst). The observed Υ(1S) suppression increases with the centrality of the collision and no significant variation is observed as a function of transverse momentum and rapidity.
ϒ production in p–Pb interactions is studied at the centre-of-mass energy per nucleon–nucleon collision √sNN = 8.16 TeV with the ALICE detector at the CERN LHC. The measurement is performed reconstructing bottomonium resonances via their dimuon decay channel, in the centre-of-mass rapidity intervals 2.03 < ycms < 3.53 and −4.46 < ycms < −2.96, down to zero transverse momentum. In this work, results on the ϒ(1S) production cross section as a function of rapidity and transverse momentum are presented. The corresponding nuclear modification factor shows a suppression of the ϒ(1S) yields with respect to pp collisions, both at forward and backward rapidity. This suppression is stronger in the low transverse momentum region and shows no significant dependence on the centrality of the interactions. Furthermore, the ϒ(2S) nuclear modification factor is evaluated, suggesting a suppression similar to that of the ϒ(1S). A first measurement of the ϒ(3S) has also been performed. Finally, results are compared with previous ALICE measurements in p–Pb collisions at √sNN = 5.02 TeV and with theoretical calculations.
Υ production in p-Pb interactions is studied at the centre-of-mass energy per nucleon-nucleon collision sNN−−−√ = 8.16 TeV with the ALICE detector at the CERN LHC. The measurement is performed reconstructing bottomonium resonances via their dimuon decay channel, in the centre-of-mass rapidity intervals 2.03<ycms<3.53 and −4.46<ycms<−2.96, down to zero transverse momentum. In this work, results on the inclusive Υ(1S) production cross section as a function of rapidity and transverse momentum are presented. The corresponding nuclear modification factor shows a suppression of the Υ(1S) yields with respect to pp collisions, both at forward and backward rapidity. This suppression is stronger in the low transverse momentum region and shows no significant dependence on the centrality of the interactions. Furthermore, the Υ(2S) nuclear modification factor is also evaluated, suggesting a suppression similar to that of the Υ(1S). A first measurement of the Υ(3S) has also been performed. Finally, results are compared with previous measurements performed by ALICE in p-Pb collisions at sNN−−−√ = 5.02 TeV and with theoretical calculations.
Υ production in p-Pb interactions is studied at the centre-of-mass energy per nucleon-nucleon collision sNN−−−√ = 8.16 TeV with the ALICE detector at the CERN LHC. The measurement is performed reconstructing bottomonium resonances via their dimuon decay channel, in the centre-of-mass rapidity intervals 2.03<ycms<3.53 and −4.46<ycms<−2.96, down to zero transverse momentum. In this work, results on the inclusive Υ(1S) production cross section as a function of rapidity and transverse momentum are presented. The corresponding nuclear modification factor shows a suppression of the Υ(1S) yields with respect to pp collisions, both at forward and backward rapidity. This suppression is stronger in the low transverse momentum region and shows no significant dependence on the centrality of the interactions. Furthermore, the Υ(2S) nuclear modification factor is also evaluated, suggesting a suppression similar to that of the Υ(1S). A first measurement of the Υ(3S) has also been performed. Finally, results are compared with previous measurements performed by ALICE in p-Pb collisions at sNN−−−√ = 5.02 TeV and with theoretical calculations.
ϒ production and nuclear modification at forward rapidity in Pb–Pb collisions at √sNN = 5.02TeV
(2021)
The production of ϒ mesons in Pb–Pb collisions at a centre-of-mass energy per nucleon pair √sNN = 5.02 TeV is measured with the muon spectrometer of the ALICE detector at the LHC. The yields as well as the nuclear modification factors are determined in the forward rapidity region 2.5 < y < 4.0, as a function of rapidity, transverse momentum and collision centrality. The results show that the production of the ϒ(1S) meson is suppressed by a factor of about three with respect to the production in proton–proton collisions. For the first time, a significant signal for the ϒ(2S) meson is observed at forward rapidity, indicating a suppression stronger by about a factor 2–3 with respect to the ground state. The measurements are compared with transport, hydrodynamic, comover and statistical hadronisation model calculations.
ϒ production and nuclear modification at forward rapidity in Pb–Pb collisions at √sNN = 5.02 TeV
(2021)
The production of Υ mesons in Pb-Pb collisions at a centre-of-mass energy per nucleon pair sNN−−−√ = 5 TeV is measured with the muon spectrometer of the ALICE detector at the LHC. The yields as well as the nuclear modification factors are determined in the forward rapidity region 2.5<y<4.0, as a function of rapidity, transverse momentum and collision centrality. The results show that the production of the Υ(1S) meson is suppressed by a factor of about three with respect to the production in proton-proton collisions. For the first time, a significant signal for the Υ(2S) meson is observed at forward rapidity, indicating a suppression stronger by about a factor 2-3 with respect to the ground state. The measurements are compared with transport, hydrodynamic, comover and statistical hadronisation model calculations.
ϒ production and nuclear modification at forward rapidity in Pb–Pb collisions at √sNN = 5.02 TeV
(2020)
The production of Υ mesons in Pb-Pb collisions at a centre-of-mass energy per nucleon pair sNN−−−√ = 5 TeV is measured with the muon spectrometer of ALICE at the LHC. The yields as well as the nuclear modification factors are determined in the forward rapidity region 2.5<y<4.0, as a function of rapidity, transverse momentum and collision centrality. The results show that the production of Υ(1S) is suppressed by a factor of about three with respect to the production in proton-proton collisions. For the first time, a significant Υ(2S) signal is observed at forward rapidity, indicating a suppression stronger by about a factor 2-3 with respect to the ground state. The measurements are compared with transport, hydrodynamic, comover and statistical hadronisation model calculations.
Results are presented on Omega production in central Pb+Pb collisions at 40 and 158 AGeV beam energy. Given are transverse-mass spectra, rapidity distributions, and total yields for the sum Omega+Antiomega at 40 AGeV and for Omega and Antiomega separately at 158 AGeV. The yields are strongly under-predicted by the string-hadronic UrQMD model and are in better agreement with predictions from a hadron gas models. PACS numbers: 25.75.Dw
The first measurement of ϕ-meson production in p-Pb collisions at a nucleon-nucleon centre-of-mass energy sNN−−−√ = 5.02 TeV has been performed with the ALICE apparatus at the LHC. The ϕ-mesons have been identified in the dimuon decay channel in the transverse momentum (pT) range 1<pT<7 GeV/c, both in the p-going (2.03<y<3.53) and the Pb-going (−4.46<y<−2.96) directions, where y stands for the rapidity in the nucleon-nucleon centre-of-mass. Differential cross sections as a function of transverse momentum and rapidity are presented. The forward-backward asymmetry for ϕ-meson production is measured for 2.96<|y|<3.53, resulting in a factor ∼0.5 with no significant pT dependence within the uncertainties. The pT dependence of the ϕ nuclear modification factor RpPb exhibits an enhancement up to a factor 1.6 at pT = 3-4 GeV/c in the Pb-going direction. The pT dependence of the ϕ-meson cross section in pp collisions at s√ = 2.76 TeV, which is used to determine a reference for the p-Pb results, is also presented here for 1<pT<5 GeV/c and 2.5<y<4.
The first study of ϕ-meson production in p-Pb collisions at forward and backward rapidity, at a nucleon-nucleon centre-of-mass energy sNN−−−√=5.02~TeV, has been performed with the ALICE apparatus at the LHC. The ϕ-mesons have been identified in the dimuon decay channel in the transverse momentum (pT) range 1<pT<7 GeV/c, both in the p-going (2.03<y<3.53) and the Pb-going (−4.46<y<−2.96) directions, where y stands for the rapidity in the nucleon-nucleon centre-of-mass, the integrated luminosity amounting to 5.01±0.19~nb−1 and 5.81±0.20~nb−1, respectively, for the two data samples. Differential cross sections as a function of transverse momentum and rapidity are presented. The forward-backward ratio for ϕ-meson production is measured for 2.96<|y|<3.53, resulting in a ratio ∼0.5 with no significant pT dependence within the uncertainties. The pT dependence of the ϕ nuclear modification factor RpPb exhibits an enhancement up to a factor 1.6 at pT = 3-4 GeV/c in the Pb-going direction. The pT dependence of the ϕ-meson cross section in pp collisions at s√ = 2.76 TeV, which is used to determine a reference for the p-Pb results, is also presented here for 1<pT<5 GeV/c and 2.5<y<4 for a 78±3~nb−1 integrated luminosity sample.
The first study of ϕ-meson production in p-Pb collisions at forward and backward rapidity, at a nucleon-nucleon centre-of-mass energy sNN−−−√=5.02~TeV, has been performed with the ALICE apparatus at the LHC. The ϕ-mesons have been identified in the dimuon decay channel in the transverse momentum (pT) range 1<pT<7 GeV/c, both in the p-going (2.03<y<3.53) and the Pb-going (−4.46<y<−2.96) directions, where y stands for the rapidity in the nucleon-nucleon centre-of-mass, the integrated luminosity amounting to 5.01±0.19~nb−1 and 5.81±0.20~nb−1, respectively, for the two data samples. Differential cross sections as a function of transverse momentum and rapidity are presented. The forward-backward ratio for ϕ-meson production is measured for 2.96<|y|<3.53, resulting in a ratio ∼0.5 with no significant pT dependence within the uncertainties. The pT dependence of the ϕ nuclear modification factor RpPb exhibits an enhancement up to a factor 1.6 at pT = 3-4 GeV/c in the Pb-going direction. The pT dependence of the ϕ-meson cross section in pp collisions at s√ = 2.76 TeV, which is used to determine a reference for the p-Pb results, is also presented here for 1<pT<5 GeV/c and 2.5<y<4 for a 78±3~nb−1 integrated luminosity sample.
ϕ meson measurements provide insight into strangeness production, which is one of the key observables for the hot medium formed in high-energy heavy-ion collisions. ALICE measured ϕ production through its decay in muon pairs in Pb-Pb collisions at sNN−−−√ = 2.76 TeV in the intermediate transverse momentum range 2<pT<5 GeV/c and in the rapidity interval 2.5<y<4. The ϕ yield was measured as a function of the transverse momentum and collision centrality. The nuclear modification factor was obtained as a function of the average number of participating nucleons. Results were compared with the ones obtained via the kaon decay channel in the same pT range at midrapidity. The values of the nuclear modification factor in the two rapidity regions are in agreement within uncertainties.
ϕ meson measurements provide insight into strangeness production, which is one of the key observables for the hot medium formed in high-energy heavy-ion collisions. ALICE measured ϕ production through its decay in muon pairs in Pb-Pb collisions at sNN−−−√ = 2.76 TeV in the intermediate transverse momentum range 2<pT<5 GeV/c and in the rapidity interval 2.5<y<4. The ϕ yield was measured as a function of the transverse momentum and collision centrality. The nuclear modification factor was obtained as a function of the average number of participating nucleons. Results were compared with the ones obtained via the kaon decay channel in the same pT range at midrapidity. The values of the nuclear modification factor in the two rapidity regions are in agreement within uncertainties.
Hadronic resonances are used to probe the hadron gas produced in the late stage of heavy-ion collisions since they decay on the same timescale, of the order of 1 to 10 fm/c, as the decoupling time of the system. In the hadron gas, (pseudo)elastic scatterings among the products of resonances that decayed before the kinetic freeze-out and regeneration processes counteract each other, the net effect depending on the resonance lifetime, the duration of the hadronic phase, and the hadronic cross sections at play. In this context, the Σ(1385)± particle is of particular interest as models predict that regeneration dominates over rescattering despite its relatively short lifetime of about 5.5 fm/c. The first measurement of the Σ(1385)± resonance production at midrapidity in Pb-Pb collisions at sNN−−−√=5.02 TeV with the ALICE detector is presented in this Letter. The resonances are reconstructed via their hadronic decay channel, Λπ, as a function of the transverse momentum (pT) and the collision centrality. The results are discussed in comparison with the measured yield of pions and with expectations from the statistical hadronization model as well as commonly employed event generators, including PYTHIA8/Angantyr and EPOS3 coupled to the UrQMD hadronic cascade afterburner. None of the models can describe the data. For Σ(1385)±, a similar behaviour as K∗(892)0 is observed in data unlike the predictions of EPOS3 with afterburner.
Hadronic resonances are used to probe the hadron gas produced in the late stage of heavy-ion collisions since they decay on the same timescale, of the order of 1 to 10 fm/c, as the decoupling time of the system. In the hadron gas, (pseudo)elastic scatterings among the products of resonances that decayed before the kinetic freeze-out and regeneration processes counteract each other, the net effect depending on the resonance lifetime, the duration of the hadronic phase, and the hadronic cross sections at play. In this context, the Σ(1385)± particle is of particular interest as models predict that regeneration dominates over rescattering despite its relatively short lifetime of about 5.5 fm/c. The first measurement of the Σ(1385)± resonance production at midrapidity in Pb-Pb collisions at sNN−−−√=5.02 TeV with the ALICE detector is presented in this Letter. The resonances are reconstructed via their hadronic decay channel, Λπ, as a function of the transverse momentum (pT) and the collision centrality. The results are discussed in comparison with the measured yield of pions and with expectations from the statistical hadronization model as well as commonly employed event generators, including PYTHIA8/Angantyr and EPOS3 coupled to the UrQMD hadronic cascade afterburner. None of the models can describe the data. For Σ(1385)±, a similar behaviour as K∗(892)0 is observed in data unlike the predictions of EPOS3 with afterburner.
An invariant differential cross section measurement of inclusive π0 and η meson production at mid-rapidity in pp collisions at s√=8 TeV was carried out by the ALICE experiment at the LHC. The spectra of neutral mesons π0 and η were measured in transverse momentum ranges of 0.3<pT<35 GeV/c and 0.5<pT<35 GeV/c, respectively. Next-to-leading order perturbative QCD calculations using fragmentation functions DSS14 for π0 and AESSS for η overestimate the cross sections of both neutral mesons, but agree with the measured η/π0 ratio within uncertainties. The results are also compared with PYTHIA~8.2 predictions for which the Monash~2013 tune yields the best agreement with the measured neutral meson spectra. The measurements confirm a universal behavior of the η/π0 ratio seen for NA27, PHENIX and ALICE data for pp collisions from s√=27.5 GeV to s√=8 TeV within experimental uncertainties. A relation between the π0 and η production cross sections for pp collisions at s√=8 TeV is given by mT scaling for pT>3.5 GeV/c. However, a deviation from this empirical scaling law is observed for transverse momenta below pT<3.5 GeV/c in the η/π0 ratio with a significance of 6.2σ.